Emglev Therapeutics


Emglev is a French-based biotechnology company founded in 2023 as a spin-off of Institut Curie focused the discovery and the development of innovative immunotherapies for the treatment of high unmet medical needs in oncology.
Leveraging its unique full stack sdAb proprietary platform and its deep expertise Emglev unlocks the current barriers of conventional antibody discovery by providing unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target.
Driven by the therapeutic need, Emglev is currently developing a diversified pipeline focused on the treatment of solid tumors. To maximize the benefit of its platform for the patients, Emglev will extend its therapeutic arsenal to a wide range of indications with major medical needs such as inflammatory and infectious diseases.